Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
1 Unique sponsors
1 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase III: 2 Phase II: 1 Phase I (Other): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • Inozyme Pharma Inc. Commercial
    RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1
    2023-507382-26-00 2 countries 2024 n=8 Orphan
    Ended
  • Inozyme Pharma Inc. Commercial
    RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1
    2024-512991-36-00 5 countries 2024 n=6 Orphan
    Recruiting

Phase II

1 trial
  • Inozyme Pharma Inc. Commercial
    RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1
    2024-512715-42-00 2 countries 2024 n=14 Orphan
    Recruiting

Phase I (Other)

1 trial
  • Inozyme Pharma Inc. Commercial
    RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1
    2023-507384-20-00 1 country 2024 n=2 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Inozyme Pharma Inc. Commercial 4 Phase I (Other), Phase II, Phase III 2
New trials by year
2024
4
← All indication landscapes